5-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice

Paper. Du Y, Zhao X, Chen Q et al.. Chinese Medical Journal, 15 Sep 2026.

Tags: Animal, Psilocybin.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 7: Do you need the trip for the benefit?

In a mouse model of autism, one dose of psilocybin made the animals lastingly more social, even when it was given under anesthesia. A second mouse study found psilocybin still helped fear extinction when the 5-HT2A receptor, the one behind the trip, was blocked. A commentary in the International Journal of Drug Policy argues that removing the experience removes much of the therapy.

How much weight it carries: Both findings are in mice. Whether the experience matters in humans is still open. (Mice, Preclinical, Peer reviewed)

Weekly Science Digest, 12 Sep 2026 to 18 Sep 2026, finding 2: How much does 5-HT2A actually do?

Blocking 5-HT2A failed to abolish psilocybin's fear-extinction and BDNF effects in mice.

Pretreatment with ketanserin or the selective antagonist MDL100907 left psilocybin's facilitation of extinction, hippocampal and prefrontal BDNF, and dentate doublecortin counts largely intact. Separately, a single 1 mg/kg dose restored novel-mouse investigation in SAPAP3 knockouts seven days later — in males only.

Read the original

—
Node—
Statuslive
Throughput—